A b s t r a c t
Malignant lymphomas are neoplasms of lymphocytes and their precursors. The main categories in the World Health Organization 2008 classification are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). 1 After initial treatment, between 25% and 85% of patients with malignant lymphomas, depending on the subtype, show relapses following a period of complete remission (CR). [2] [3] [4] [5] The second and subsequent occurrence is usually considered a recurrence of the original tumor, even after many years of CR. However, a second occurrence of malignant lymphoma may also be an unrelated primary malignant lymphoma, especially after a long period of CR.
It is clinically relevant to differentiate between a recurrence and an unrelated primary lymphoma because the treatment strategy is usually different. Patients with recurrent lymphoma are usually treated aggressively, whereas patients with unrelated primary lymphomas generally receive the standard first-line therapies. Currently, little information is available with regard to the relative incidences of recurrent lymphoma and unrelated primary lymphoma. In previous studies, the percentage of patients with unrelated primary lymphomas rather than lymphoma recurrences ranged from 15% to 100%, [6] [7] [8] [9] [10] [11] [12] as summarized in ❚Table 1❚. Limitations of these studies include their focus on particular lymphoma subtypes, the small sample sizes, or both. If the incidences of recurrences vs unrelated primary lymphomas were better documented, a better decision could be made on whether to perform molecular analysis to investigate the possible clonal relationship between successive lymphomas. To our knowledge, no such studies have been performed in a large clinical setting.
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Using a single-center cohort consisting of all subtypes of B-cell lymphomas, we addressed whether successive B-cell lymphomas, diagnosed within a 5-to 15-year interval, are recurrences or unrelated primary lymphomas. Initially, 61 patients with multiple B-cell lymphomas were eligible for this study. Multiplex polymerase chain reaction (PCR) fragment assays were used to study rearrangements of the immunoglobulin heavy (IGH) and k light chain (IGK) genes in all lymphomas. Clonal patterns of the multiple lymphomas from 36 patients could be determined. When different fragment sizes were found in successive lymphomas of a patient, the rearrangements were sequenced to verify their different origin.
Materials and Methods

Material Selection
We studied a cohort of patients with a B-cell lymphoma, including HL, diagnosed between January 1, 1985, and September 21, 2011, at the Erasmus Medical Center, Rotterdam, the Netherlands. Patients were selected using the pathology laboratory information system Sympathy (Tieto, Helsinki, Finland). Using the Dutch pathologic anatomy national automated archive (PALGA), all PALGA codes containing lymphoma and excluding bone marrow or containing Hodgkin and excluding lymphoma were selected. Within these groups, a total of 163 patients had multiple lymphomas within a 5-to 15-year interval, with the most recent lymphoma being diagnosed in 2000 or later.
Subsequently, all patient histories were manually checked for the actual occurrence of multiple lymphomas and the availability of sufficient material for DNA analysis, resulting in the exclusion of 18 patients. Furthermore, patients with T-cell malignancies (n = 15) and patients treated outside the Erasmus Medical Center (n = 51) were excluded. The remaining 79 patients were categorized according to the diagnosis of the most recent lymphoma into 1 of the following groups: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary cutaneous follicle center lymphoma (PCFCL), marginal zone lymphoma (MZL), mantle cell lymphoma, chronic lymphocytic leukemia (CLL), HL, or NHL not otherwise specified (NHL-NOS). Remission statuses were derived from the hospital records. These statuses were determined according to the internationally accepted criteria, the most recent from Cheson et al. 13 Of these patients, all available lymphoma tissues were included in the analysis, also when diagnosed outside the specified interval. All diagnoses of lymphoma were reviewed by an experienced hematopathologist (K.H.L.). If necessary, additional immunohistochemistry was performed and patients were recategorized accordingly. Patients were excluded when stainings (n = 8) or formalin-fixed, paraffin-embedded (FFPE) tissue blocks (n = 8) were not available. Furthermore, another 2 patients were excluded because they eventually did not fulfill all selection criteria. In the end, a total of 61 (37%) of the initially selected 163 patients were included for analysis, resulting in 183 tissue samples in FFPE blocks.
DNA Isolation
From FFPE tissue blocks, 5 to 30 sections of 4 mm were cut depending on the size of the tissue. Tumor tissue was manually microdissected from 5 to 15 hematoxylin-stained sections when the tumor percentage was below 5% or when multiple lymphomas were present in 1 tissue block. Additional DNA was isolated from frozen tissue or dissected from routine cytologic specimens (if present) when distinct rearrangements were found in successive lymphomas of a patient.
DNA was extracted using proteinase K (Roche Diagnostics, Indianapolis, IN) and 5% Chelex 100 resin (Bio-Rad, Hercules, CA), as previously described. 14 
Clonality Analysis
To check the quality of the samples, we performed a multiplex control PCR as previously described 15 with undiluted DNA and 1:10 and 1:50 dilutions. The dilution with the best results in agarose gel electrophoresis was selected for further analysis.
Multiplex BIOMED-2 PCR fragment assays were used to study rearrangements of the IGH and IGK genes in all samples. These assays were performed according to standardized protocols and primers. 15 IGH framework 1, 2, and 3 assays (IGH-A, IGH-B, and IGH-C) were used to detect Vh-Jh rearrangements, and IGH-D was used for the detection of incomplete Dh-Jh rearrangements. Vk-Jk rearrangements and functionally inactivating recombinations involving Kde (Vk-Kde or intron-Kde) were detected using IGK-A and IGK-B assays, respectively. The fragments were detected by GeneScan analysis on an ABI 3130XL genetic analyzer (Applied Biosystems, Foster City, CA), and data were analyzed with Peak Scanner Software version 2.1 (Applied Biosystems). Results were scored manually following recently described guidelines. 16 When different PCR product sizes were found within multiple lymphomas of a patient or when results were ambiguous, analyses were repeated.
Sequence Analysis
When distinct rearrangements were found in multiple lymphomas of a patient, the fragments were sequenced to verify their different origin. The IGH or IGK gene rearrangements were amplified using unlabeled multiplex BIOMED-2 PCR assays. 15 Subsequently, heteroduplex analysis was performed to identify the presence of 1 or more clonal bands. 17 If a sample showed multiple homoduplexes or when aspecific bands were present, bands were cut from the polyacrylamide gel and eluted prior to sequencing. Single clonal PCR products were purified using ExoSAP-IT (Affymetrix, Santa Clara, CA) according to the manual.
Sequencing was performed using the consensus Jh primer for IGH fragments, Jk1-4 and Jk5 primers for IGK-A fragments, and the Kde primer for IGK-B fragments. The BigDye Terminator version 3.1 Cycle Sequencing Kit was used for sequencing, after which products were purified using the BigDye Xterminator Purification Kit (both from Applied Biosystems), according to the manuals. The labeled fragments were detected on an ABI 3130XL genetic analyzer (Applied Biosystems). Data were analyzed with CLC DNA workbench version 5.7 (CLC Bio, Aarhus, Denmark). The involved Vh or Vk family member was identified using the IMGT/V-Quest alignment tool, version 3.2.25 (www. imgt.org/IMGT_vquest/vquest). Next, a Vh or Vk family primer was used to perform a monoplex PCR reaction from which the product was bidirectionally sequenced.
When DNA quality was not sufficient to identify the Vh or Vk family member using a multiplex PCR approach, PCR reactions were performed with all V family primers in monoplex reactions. If necessary, multiplex or monoplex PCR products were cloned into a pGEM-T easy vector (Promega, Madison, WI). Single-colony PCR was performed on the positive clones; the PCR products were directly sequenced.
Data Analysis and Classification of Results
Multiple lymphomas with an interval of at least 5 years were classified as (a) recurrences, when 2 or more independent rearrangements showed the same fragment size; (b) possible recurrences, when only 1 interpretable marker showed identical sizes; (c) different clones with a common origin, when fragment size differences as well as similarities between the lymphomas were found; (d) unrelated primary lymphomas, when differences were found between the lymphomas in 1 or 2 markers, with at least 2 interpretable markers; or (e) nonevaluable, if they did not fit the other categories.
Results
A total of 61 patients with multiple lymphomas diagnosed within a 5-to 15-year interval were selected for analysis. Of these patients, all available lymphoma tissues were included in the analysis. Several of these additional lymphomas were diagnosed within the specified interval, shortening the remission time between 2 consecutive occurrences of lymphoma. ❚Figure 1❚ shows a chronological overview of the multiple lymphomas for the 36 patients with evaluable results. For these patients, the interval between any 2 consecutive lymphomas ranged from 2 to 12 years. All CRs, partial remissions, and additional lymphomas for which no tissue was available, established within the intervals between the multiple lymphomas, are included as far as known based on the hospital records.
IGH and IGK Clonality Analysis Points to a High Frequency of Lymphoma Recurrence
Rearrangements of IGH and IGK genes were analyzed in DNA isolated from 61 patients. In the first 11 samples, all rearrangements involving the variable domains of IGH and IGK were tested using the BIOMED-2 IGH-A, IGH-B, IGH-C, IGK-A, and IGK-B assays. Targets IGH-C and IGK-A gave the best results, with relative small product sizes of 100 to 300 base pairs (bp). This corresponded to the results of the control PCR, which showed that DNA quality was often compromised. Therefore, IGH-C and IGK-A were selected as the first targets to be tested in all other samples. However, targets IGH-C and IGK-A did not provide sufficient information to assess whether tissues were clonally related for 30 patients. 1 9 8 4 1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0 2 0 1 1 A B of different sizes in their samples ❚Image 1E❚, ❚Image 1F❚, ❚Image 1G❚, and ❚Image 1H❚. For these patients, all markers were analyzed. Figure 1 shows for each lymphoma whether the clonal patterns were scored as identical (at least 2 rearrangements of identical fragment size), possibly identical (only 1 rearrangement with the same fragment size), different, or nonevaluable. The results of IGH and IGK clonality analysis for all patients are provided in ❚Table 3❚.
Sequencing of Differently Sized Fragments Shows Evidence for Clonally Related and Unrelated Lymphomas
From the 5 patients with differently sized immunoglobulin-rearranged products in their multiple lymphoma samples, DNA was isolated from additional FFPE, frozen, and cytologic tissue if available. All 6 IGH and IGK targets were analyzed in these extra samples. To check whether the differently sized fragments in the patients represented independent rearrangements, we also sequenced the fragments ❚Table 4❚.
Patient D3 showed an IGH-C fragment of 143 bp in the FL from 1998, whereas the DLBCL from 1998, 2002, and 2004 showed 118-bp fragments. After sequencing, the FL showed a dominant IGH-C fragment involving IGHV4-34 and a minor fragment involving IGHV3. This minor fragment was not visible during fragment analysis. All other samples from this patient showed only 1 fragment, identical to the IGHV3 rearrangement. The DNA from the FL was isolated from a tissue block containing a DLBCL/FL composite lymphoma. The minor fragment involving IGHV3 found in the FL is therefore most likely due to cells from the DLBCL. sequenced. The patient was finally classified as having different lymphoma clones with a common origin.
No Obvious Relation Exists Between Occurrence of Unrelated Lymphomas and Time Interval
Overall, clonal patterns of the successive lymphomas from 36 patients could be determined and were classified accordingly: 30 recurrences, 2 possible recurrences, 2 different clones with a common origin, and 2 unrelated primary lymphomas. In both patients with unrelated primary lymphomas, the most recent lymphoma was diagnosed as a DLBCL. To study the possible association between occurrence of unrelated lymphoma and interval, we examined in more detail the intervals between the consecutive lymphomas. Of the 36 patients with evaluable results, 2 patients had an interval of more then 10 years between their consecutive lymphoma recurrences. Eighteen patients had an interval of 5 to 10 years between 2 consecutive occurrences of lymphoma: 15 recurrences, 1 possible recurrence, and 2 different clones with a common origin. All other patients had an interval of less than 5 years between their consecutive lymphomas.
Finally, we wanted to evaluate whether unrelated lymphomas occur in defined lymphoma subtypes. For 2 subtypes of lymphoma relapses, DLBCL and FL, we included at least 10 patients, with 14 and 10 patients with evaluable results, respectively. The DLBCL relapses were classified as follows: 10 recurrences, 1 possible recurrence, 1 different clone with a common origin, and 2 unrelated primary lymphomas. All FL relapses were recurrent lymphomas.
Discussion
Our study shows that, regardless of the subtype, 89% to 94% of late B-cell lymphoma relapses diagnosed within a 5-to junction, resulting in the observed size difference. This patient showed 2 identically sized rearrangements involving the Kde element in all samples. One of these rearrangements involving VK1 was successfully sequenced in the FL from 2003 and the DLBCL from 2010 and turned out to be identical. Therefore, this patient was classified as having different lymphoma clones with a common origin.
Patient D8 showed an IGH-C fragment of 149 bp for the DLBCL from 2004, as well as 112-bp fragments for the Waldenström macroglobulinemia (WM) samples from 1999 and 2001. Sequencing revealed a fragment involving IGHV5-51 for the DLBCL, and the WM samples showed a fragment involving IGHV3. All samples had an identically sized fragment of 150 bp with marker IGK-A. However, the DLBCL and WM rearrangements showed involvement of different V genes as well as different junctions. This patient was classified as having unrelated primary lymphomas.
Patient F15 showed differences for target IGK-A, with a 280-bp fragment for the FL from 2010 and a 151-bp fragment for the FL from 1995. Surprisingly, these samples showed an identically sized fragment on polyacrylamide gel and a nearly identical rearrangement involving Vk4-1. After reexamination of the fragment analysis results, a very low 281-bp peak was found for the FL from 1995. In addition, the samples showed identically sized IGH rearrangements. Therefore, these lymphomas were classified as clonally identical recurrences.
Patient O2 showed multiple fragments in targets IGH-C and IGK-A, some of which were mutually exclusive between the NHL from 1991 and the NHL from 1997 and 2000. This was true for the 124-bp and 109-bp fragments, respectively, for target IGH-C. For IGK-A, a 152-bp fragment was present in all samples except the NHL from 1991. However, in all samples, 2 and 3 additional identically sized fragments were found in targets IGH-C and IGK-A, respectively. Because of the complex rearrangement patterns, these samples were not different V genes and junctions were observed. Therefore, we suggest performing fragment analysis of at least 2 independent rearrangements when determining whether 2 occurrences of lymphoma are clonally related. The 2 patients in this study with unrelated primary lymphomas showed different rearranged IGH fragments between their successive lymphomas. As only 1 IGH rearrangement was found for each lymphoma, the question arises whether these lymphomas are really different or could have a common origin possibly represented by a second undetected IGH rearrangement. Furthermore, clonally distinct relapses can also be recurrences from a subclone in the primary lymphoma. Previously, FL and DLBCL recurrences have been described for which the mutation patterns of the rearrangements were nearly identical to that of minor subclones in the primary FL. 18, 19 In this study, however, both patients with unrelated primary lymphomas showed involvement of different IGHV genes in their successive lymphomas, making it unlikely that the relapses were subclones of the primary lymphomas.
For both patients with clonally unrelated primary lymphoma relapses, the morphology of the clonally distinct relapse was different from that of the primary lymphoma. Patient D3 presented with a DLBCL/FL composite lymphoma in 1998 and with DLBCL relapses after 4 and 6 years. The FL was clonally distinct from the multiple occurrences of DLBCL, which were all related. Patient D8 presented with WM in 1999 and 2001. In 2004, the patient was diagnosed with a relapse suggestive of transformation of the lymphoma to a DLBCL. However, this relapse was not clonally related to the WM. In 6 of 10 patients with DLBCL recurrences, the primary tumor was also of a different morphology. These patients showed 15-year interval are recurrences of the primary tumor. Only 2 of 36 (6%) successive lymphomas actually concerned clonally unrelated primary lymphomas. In both cases (patients D3 and D8), the most recent lymphoma was diagnosed as a DLBCL.
Although the most commonly used assay for determining whether 2 lymphomas are clonally related is fragment analysis of IGH and IGK rearrangements, there are some limitations to this approach. Ongoing somatic hypermutations are a common event in lymphomas, especially in FL. Only hypermutations resulting in deletions or insertions will be detected using fragment analysis. All FL in this study showed identical fragment sizes, suggesting that no deletions or insertions occurred in these lymphomas despite the large intervals. Differently sized fragments, however, can still represent the same rearranged fragment. In the current study, sequencing analysis was performed when differently sized fragments were found to see whether these differences truly reflect different tumor origins. The successive lymphomas of patient D4 showed differently sized IGH fragments both involving IGHV3 but with differences between the sequences and junctions. However, this patient showed 2 identically sized inactivating rearrangements involving the Kde element, one of which was confirmed by sequencing analysis. Despite the observed differences with the IGH marker, these lymphomas seem to have a common clonal origin. Furthermore, identically sized fragments found in 2 lymphomas can still represent 2 different rearrangements, as shown by Nishiuchi et al. 11 The successive lymphomas of patient D8 showed an identically sized fragment with marker IGK-A. However, differently sized IGH fragments involving different V genes were found. The identically sized IGK fragment is due to the restricted IGK junctional heterogeneity, as DLBCL. This is in contrast to previous studies that report a considerable number of patients with unrelated primary lymphomas rather than recurrences. High incidences of unrelated primary lymphomas were suggested in cases of HL relapses 6, 7 and central nervous system relapses. 8 For these subtypes of lymphoma, we unfortunately do not have enough data available. Overall, our results and those of others suggest that the incidence of unrelated primary lymphomas varies between different subtypes of relapses and primary lymphomas.
Even after a longer interval, we did not find a higher occurrence of unrelated primary lymphomas. Two patients had an interval of more than 10 years between their consecutive lymphomas; these patients were diagnosed with recurrences after a CR of 11 years. Furthermore, 18 patients who had an interval of 5 to 10 years between their consecutive lymphomas did not show unrelated primary lymphomas. The 2 patients with unrelated primary lymphomas had intervals of less than 5 years between their consecutive occurrences of lymphoma. It is also remarkable that 1 of these patients had only partial remission; apparently, this does not exclude the occurrence of a new unrelated primary lymphoma.
Twenty-five patients who had ambiguous results were classified as nonevaluable. DNA was isolated from FFPE tissue blocks due to the high availability of this tissue. Unfortunately, DNA quality was compromised as a result of fixation artifacts. The highest percentages of nonevaluable patients were in the PCFCL and HL subgroups-for 3 of 4 and 5 of 6 patients, respectively, clonal patterns of the successive lymphomas could not be determined. This could be explained by the combination of compromised DNA quality and the low amount of tumor cells in the tissues. The use of different patient tissues, especially for small-sized lymphomas, is therefore preferred.
In conclusion, late relapses of lymphomas are mostly recurrences of the primary tumor. Therefore, routine investigation of the possible clonal relationship between 2 successive occurrences of lymphoma is not warranted given the high costs of the molecular assays. However, for specific subgroups of lymphoma, additional extensive molecular analysis might be valuable, especially for DLBCL recurrences.
To better document the incidence of unrelated primary lymphomas for specific lymphoma subtypes, a larger cohort is required, especially for lymphomas that are less common. Furthermore, it is important to perform sequencing analysis when differently sized fragments are found to confirm that these differences truly reflect independent rearrangements. To do this, it might be necessary to use patient tissues that are not formalin fixed to improve DNA quality. clonally related DLBCL recurrences from FL, CLL, or MZL. Histologic transformations of multiple lymphoma subtypes to DLBCL have been reported extensively. 20 Thus, a DLBCL relapse from a morphologically different primary tumor by itself is not an indication of unrelated primary lymphomas.
Patient D17 presented with CLL in 1995 and 2000, as well as DLBCL/aggressive CLL in 2003; these lymphomas were clonally identical recurrences. In situ hybridization was performed to detect Epstein-Barr virus (EBV)-encoded RNA in the CLL and DLBCL samples of this patient, and a few positive nuclei were found. Because of the minimal amount of positive small nuclei, we are inclined to interpret this finding as a latent persistent EBV infection. However, we cannot exclude an oncogenic role in this respect, as other reports have demonstrated this. 21, 22 Previous studies reported higher frequencies of unrelated primary lymphomas instead of recurrences; however, these studies focused on subtypes of lymphoma. The single-center cohort used in the current study resulted in 36 patients with clonal patterns that could be determined, including multiple subtypes of lymphoma. The largest subgroups were DLBCL and FL relapses, consisting of 14 and 10 patients, respectively. Within the subgroup of patients with DLBCL relapses, 2 of 14 patients had unrelated primary lymphomas. Correspondingly, de Jong et al 9 studied DLBCL recurrences after 4 to 17 years; in 2 of 13 patients, they found evidence for clonally unrelated primary lymphomas. Nishiuchi et al 11 studied 3 patients with DLBCL recurrences, 1 of whom was suggested to have unrelated primary lymphomas. All FL relapses turned out to be recurrent lymphomas. Unrelated primary lymphomas were not found in any subtype of lymphoma relapses besides 
